Clinical Trial Update: Detection of Methylated Reprimo in Plasma for Asymptomatic Gastric Cancer

View source ↗

Summary

A clinical trial is evaluating whether methylated Reprimo in plasma can serve as a biomarker for asymptomatic gastric cancer, focusing on early gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Snippet

Sponsor: Pontificia Universidad Catolica de Chile | Conditions: Early Gastric Cancer | Status: UNKNOWN